BridgeMD
New treatment option for Pneumococcal Disease
Official title A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
ClinicalTrials.gov ID: NCT07629440
What this study is testing
What is PG4?
PG4 is an investigational medicine, being studied as a potential treatment for pneumococcal disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 42 to 211. Healthy volunteers may be eligible.
You may be able to join if
- infants who are 2 months of age in Group 1.
- infants who are 2 to 6 months of age in Groups 2 and 3.
- Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.
You likely can't join if
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis).
- Major known congenital malformation or serious chronic disorder.
- Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or...
- Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Centreville, Alabama, United States
- Fayetteville, Arkansas, United States
- Jonesboro, Arkansas, United States
- Sherwood, Arkansas, United States
- Arcadia, California, United States
- El Monte, California, United States
- Fresno, California, United States
- Montebello, California, United States
- National City, California, United States
- Palo Alto, California, United States
- Aurora, Colorado, United States
- Hialeah, Florida, United States
- Homestead, Florida, United States
- Miami, Florida, United States
- Miami Lakes, Florida, United States
- North Lauderdale, Florida, United States
- Sweetwater, Florida, United States
- Norcross, Georgia, United States
- Ammon, Idaho, United States
+ 56 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 42 days to 211 days. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Centreville, Alabama, United States; Fayetteville, Arkansas, United States; Jonesboro, Arkansas, United States; Sherwood, Arkansas, United States; Arcadia, California, United States and 70 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.